A major problem in patients successfully treated with thrombolytic therapy is the recurrence of myocardial ischemia caused by coronary reocclusion. Reocclusion may lead to worsening of left ventricular function and, subsequently, prognosis. The See p 1759 Therefore, the multicenter Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT) Study was designed to compare aspirin, Coumadin, and placebo in patients with a patent infarct-related vessel after thrombolysis regarding the patency of the infarct-related vessel at 3 months, recurrent ischemic events, and changes in left ventricular function.
Methods

Study Protocol
Patients who presented with chest pain of <4 hours and >30 minutes of duration and a minimum of 0.2 mV ST-segment elevation in two contiguous ECG leads, suggestive of acute myocardial infarction, were treated with thrombolytic therapy (see Figure 1 ). Thrombolytic agents used were streptokinase and anisoylated plasminogen streptokinase activator complex (APSAC (Table 1) .
The study medication was discontinued in 20 patients in the aspirin group, in eight patients in the Coumadin group, and in 27 patients in the placebo group. In five patients who had aspirin and in six patients who had placebo, Coumadin was prescribed because of left ventricular thrombosis, deep venous thrombosis, or atrial fibrillation. Seven patients from the aspirin group received regular aspirin, as did seven patients on Coumadin and 20 patients on placebo because of suspected recurrent ischemic symptoms. Three patients assigned to aspirin treatment were switched to regular aspirin because of refusal to further participate in the trial. So, in total, in 37 of the 55 patients in whom study medication was discontinued, regular aspirin was the substitute. For several reasons, no alternative antithrombotic treatment was given to five patients in the aspirin group, to one patient in the Coumadin group, and to one patient on placebo. According to the principle of intention to treat, patients continued to be assessed by originally allocated therapy.
Angiographic Results
Overall, reocclusion occurred in 71 of 248 patients (29%; 95% confidence limits, 23-34%) (see Figure 2) . Thirteen of these patients had grade 4 stenosis, and 58 patients had grade 5 stenosis. The reocclusion rate in patients on aspirin was 23 of 93 patients (25%; 95% confidence limits, 16-34%); in those on Coumadin, 24 of 81 (30%; 95% confidence limits, 20-40%); and in those on placebo, 24 of 74 (32%; 95% confidence limits, 22-34%). Neither of the comparisons was statistically significantly different. The reocclusion rate of either of the three coronary arteries was also not significantly different (Table 2) .
There was a slight increase in ejection fraction in the patient group that underwent follow-up ventriculography from 51.0±11.1% to 53.4±12.6% (p=0.006). This is explained by the significant increase of left ventricular ejection fraction of 4.1±10.3 absolute percent (baseline ejection fraction, 50.6±10.5%) in 119 patients with persistent patency (Figure 3 ). In contrast, there was no recovery of left ventricular ejection fraction in 51 patients with reocclusion (baseline ejection fraction, 52.0±12.6%; change, -1.7±11.1%) (Figure 3) . Differences between follow-up left ventricular ejection fractions within the treatment groups were small, but by paired analysis, ejection fraction increased significantly in patients on aspirin (change, +4.6±10.8%; p<0.001), whereas there was no significant increase in the other treatment groups (Coumadin group: change, + 1.4±11.2%; placebo group: change, +0.8±11.8%). 
Clinical Results
There was a significantly lower incidence of both reinfarction and revascularization in patients on aspirin compared with placebo ( 
Combined End Points
The proportion of patients without reinfarction, revascularization, or death was significantly higher in patients treated with aspirin than in patients on Coumadin or on placebo (Figure 4) . A similar pattern was observed in patients with both an event-free clinical course and an open infarct-related vessel at 3 months. Discussion This study is the first to report a comparison of three antithrombotic regimens in the prevention of recurrent ischemia and reocclusion after successful thrombolysis for acute myocardial infarction: intravenous heparin followed by aspirin, Coumadin, or placebo. The main finding is that at 3 months, reocclusion rates are very high (mean, 29%) and not significantly different between patients allocated to aspirin, heparin/Coumadin, and placebo. The study further demonstrates a statistically significant reduction of reinfarction and revascularization in patients on aspirin compared with placebo and a lower rate of the combined outcomes of revascularization, reinfarction, and death on aspirin than on placebo or heparin/Coumadin. The importance of the superior efficacy of aspirin on these clinical end points is stressed by the fact that, of the five patients who died in this trial, death was related to symptomatic recurrent ischemia in three. The efficacy of aspirin on recurrent ischemia is corroborated by the fact that only in the aspirin group, a significant recovery of left ventricular function was observed. Heparin/Coumadin-allocated patients did no better on any end point than those on aspirin, but there were trends toward better efficacy than placebo.
Heparin and Coumadin After Thrombolysis
The role of heparin in thrombolytic therapy remains controversial. In recent studies,6-10 intravenous heparin was used as an adjunct to alteplase. Three of these studies6-8 demonstrate improvement of patency of the infarct-related artery by heparin with coronary angiography at 7-120 hours after thrombolysis, at the expense of increased bleeding rates in two. However, this was not seen at angiography after 90 minutes9 or after 7-10 days. 10 The additional value of intravenous heparin in thrombolysis with streptokinase or APSAC is unclear. The lytic state that these agents induce may increase the risk of bleeding when full-dose heparin is started early. For that reason, in the International Study Group trial" and in ISIS-3,12 subcutaneous heparin (12,500 units b.i.d.) was started no earlier than 4-12 hours after thrombolysis. In a combined analysis of these trials,12 the addition of heparin to aspirin slightly reduced the incidence of death during the scheduled treatment period from 7.3% to 6.8%, with loss of this mortality advantage at 35 days or 6 months. In ISIS-3,12 the same pattern was observed regarding the reinfarction rates. In both trials, there was a definite increase of major bleeding. In our study, in patients who were assigned to Coumadin treatment, the timing of reinfarction did not differ from the other treatment groups. Apparently, the stimulus for rethrombosis is strongest during the first days after thrombolysis and is neither reduced or delayed by our heparin regimen. It cannot be excluded that the relatively low dose of heparin we gave (started 
Reocclusion After Thrombolysis
The present study is the first to report reocclusion rates at 3 months of follow-up in a large group of patients. Although the observed overall reocclusion rate is high, it is within limits reported earlier. 17 ,23 This can be explained by the study design and the timing of follow-up coronary angiography. The wide range of reocclusion rates that have been reported previously were mainly derived from studies in which reocclusion was not a primary end point, as it was in our study. Moreover, earlier studies reported in-hospital reocclusion rates based on early angiography after thrombolytic treatment. 6, [17] [18] [19] In contrast, in our study, follow-up coronary angiography was done after 3 months, allowing a greater time window for reocclusion to occur.
Reocclusion and Left Ventricular Function
Our data strongly suggest that there is no recovery of left ventricular function after successful thrombolysis when reocclusion occurs, although these data may be subject to selection bias. If this finding is confirmed by other studies, this may indicate that the benefits of thrombolysis for left ventricular function are limited to the estimated 35-55% of patients with both successful thrombolysis and persistent patency of the infarctrelated vessel. Consequently, better prevention of reocclusion may result in further reduction of mortality after thrombolysis.
Study Limitations A limitation of our study imposed by the study design is that only patients who survived the acute phase and were fit to undergo cardiac catheterization within 48 hours, showing a patent infarct-related vessel, entered the study. This selection will have contributed to the low mortality figure that we observed and makes our study population less comparable to other study populations without proven patency of the infarct-related vessel. After interim analysis, the small differences that were found in reocclusion rates and the significantly more favorable clinical outcome in one of the treatment arms prompted us to discontinue the trial. This will have affected the statistical power of the trial to detect differences in the primary end point.
Conclusions
We conclude that at 3 months after successful thrombolysis, reocclusion occurs in almost one third of the patients and that reocclusion interferes with left ventricular recovery. When heparin is given in the acute phase, this should be followed by aspirin treatment because aspirin reduces recurrent myocardial infarction and the need for revascularization and tends to reduce angiographic reocclusion. Because the reocclusion rate is high even with aspirin, the search for better prevention of reocclusion should continue.
